Resveratrol lowers hospitalization rate for COVID outpatients

The new double-blind, placebo-controlled research was published in the journal Scientific Reports. It was the work of researchers associated with an Ohio hospital and Ohio State University.

Resveratrol is a polyphenol found in grapes, Japanese knotweed, and other botanical sources. It was originally studied for its purported ability to mimic the longevity-enhancing effects of extremely low-calorie diets.

The multimodal effects of resveratrol made it a good candidate

The researchers said resveratrol’s combination of health effects made it of particular interest in managing the effects of COVID-19 infection, which involves downregulating ACE2, a key protein involved in regulating cardiovascular function. and renal function is involved.

“Resveratrol’s multimodal antiviral, anti-inflammatory and antioxidant properties, as well as its ability to upregulate ACE2 receptors, may be helpful in reducing the clinical impact of COVID-19.”they write.

Vitamin D3 (in a single acute dose of 100,000 IU for both treatment and control groups) was administered as an adjunct “Based on previous research showing it has synergistic anti-inflammatory effects.”

The study was conducted under an IND. Researchers recruited 100 patients for the study of cold calling in patients 45 years and older who tested positive at one of the Mount Carmel Health System (Columbus, OH) testing centers.

The primary outcome of the study was the rate of hospital admissions after an initial positive COVID-19 test. At the time the study was conducted in late 2020, the hospitalization rate among confirmed cases of COVID-19 ranged from 21% in the 45-54 age group to up to 31% in patients aged 81 years and older. The researchers said subsequent analysis showed actual hospitalization rates were “much lower,” although they didn’t specify how much lower.

Leave a Comment